Compare GME & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GME | PRAX |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronics Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 9.6B |
| IPO Year | 2005 | 2020 |
| Metric | GME | PRAX |
|---|---|---|
| Price | $24.76 | $331.06 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 15 |
| Target Price | $13.50 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 5.8M | 375.2K |
| Earning Date | 03-24-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 133.33 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $3,629,900,000.00 | N/A |
| Revenue This Year | $18.98 | N/A |
| Revenue Next Year | N/A | $6,395.88 |
| P/E Ratio | $32.20 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.94 | $32.78 |
| 52 Week High | $35.81 | $354.87 |
| Indicator | GME | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 63.75 | 55.21 |
| Support Level | $22.23 | $282.49 |
| Resistance Level | $25.93 | $327.65 |
| Average True Range (ATR) | 0.71 | 18.92 |
| MACD | 0.23 | 3.50 |
| Stochastic Oscillator | 90.16 | 68.51 |
GameStop Corp offers games, collectibles, and entertainment products through its stores and ecommerce platforms. Its products include Hardware and accessories offering new and pre-owned gaming platforms from the console manufacturers, Software offering new and pre-owned gaming software for current and certain prior generation consoles and sell a wide range of in-game digital currency, digital downloadable content and full-game downloads, and Collectibles consist of apparel, toys, trading cards, gadgets and other retail products for pop culture and technology enthusiasts and collectibles related services, such as submission services for the authentication and grading of trading cards. The company operates its business in three geographic segments: the United States, Australia, and Europe.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.